Garcia-Gutierrez, ValentinLuna, AlejandroAlonso-Dominguez, Juan MEstrada, NataliaBoque, ConcepcionXicoy, BlancaGiraldo, PilarAngona, AnnaAlvarez-Larran, AlbertoSanchez-Guijo, FerminRamirez, Maria JoseMora, ElviraVelez, PatriciaRosell, AnaColorado-Araujo, MercedesCuevas, BeatrizSagües, MiguelCortes, MontserratPerez-Encinas, ManuelCasado Montero, Luis FelipeMoreno-Vega, MelaniaSerrano, LuisGomez, ValleGarcia-Hernandez, CarmenLakhwani, SunilPaz-Coll, Antoniode-Paz, RaquelSuarez-Varela, SaraFernandez-Ruiz, AndresPerez-Lopez, RaulOrtiz-Fernandez, AlmudenaJimenez-Velasco, AntonioSteegmann-Olmedillas, Juan LuisHernandez-Boluda, Juan Carlos2023-02-092023-02-092021-02-09Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021 Feb 9;11(2):16http://hdl.handle.net/10668/17137Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de CádizProtein Kinase InhibitorsPyrazolesTreatment OutcomeYoung AdultAdultAgedAged, 80 and overFemaleFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNiacinamideresearch article33563899open accessVoliciónFosfotransferasasTirosinaLeucemia mieloidePreparaciones farmacéuticas10.1038/s41408-021-00420-82044-5385PMC7873237https://www.nature.com/articles/s41408-021-00420-8.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873237/pdf